Abstract. CV-159, a 1,4-dihydropyridine derivative, has Ca 2+ antagonistic and anti-calmodulin actions. An early feature of atherosclerosis is vascular endothelial inflammatory change. We examined whether CV-159 has protective effects against endothelial inflammatory responses. After pretreatment of human umbilical vein endothelial cells (ECs) with CV-159 (10 μ M, 30 min), TNF-α (10 ng/ml) was applied for 20 min or 24 h. Expressions of inflammatory markers and activation of inflammatory signal molecules were examined by Western blotting. Reactive oxygen species (ROS) generation was examined by using 2′,7′-dichlorodihydrofluorescein diacetate. CV-159 inhibited TNF (24 h)-induced expression of e-selectin but not vascular cell adhesion molecule-1 and intercellular adhesion molecule-1. CV-159 inhibited TNF (20 min)-induced phosphorylation of JNK, p38, and NF-κ B p65 (Ser536). A JNK inhibitor, SP600125, and a p38 inhibitor, SB203580, inhibited TNF-induced e-selectin expression. An antioxidant drug, N -acetyl-L -cysteine (NAC), inhibited TNF-induced e-selectin expression. NAC inhibited TNF-induced phosphorylation of JNK and p38 but not NF-κ B. CV-159 inhibited TNF-induced ROS generation. Our results indicate that in ECs CV-159 specifically inhibits TNF-induced e-selectin expression through inhibition of JNK, p38, and NF-κ B phosphorylation. It is suggested that CV-159 prevents activation of JNK and p38 through inhibition of ROS, while it prevents activation of NF-κ B via a ROS-independent manner.
Introduction
CV-159, a 1,4-dihydropyridine derivative, is a unique Ca 2+ antagonist with a potent inhibitory effect on calmodulin (CaM) function. CV-159 inhibits both Ca 2+ / CaM-activated myosin light chain kinase and cyclic nucleotide phosphodiesterase through interacting with CaM (1) . The duration of cardiovascular actions (hypotensive and arterial blood flow increasing effects) of CV-159 in vivo is longer than that of nicardipine, another dihydropyridine Ca 2+ antagonist (2) . It was previously reported that CV-159 protected against ischemic brain injury, which was mediated by inhibiting both Ca 2+ influx and CaM function (3) . In addition, it was recently demonstrated that CV-159 has an organ-reducing activity against radicals in hepatic ischemia reperfusion injury, which was presumably mediated by inhibiting Ca 2+ overloading as well as increased reactive oxygen species (ROS) (4, 5) .
Vascular endothelial cells (ECs) inflammatory injury represents an important early pathogenic feature of atherosclerosis, which is one of the major risk factors for ischemic heart disease (6 -8) . In the present study, we hypothesized that CV-159 could prevent ECs inflammatory injury. To test the hypothesis, we examined effects of treatment of cultured ECs with CV-159 on inflammatory signal and protein expression. We found that CV-159 exerts protective effects against TNF-induced inflammatory events in vascular ECs. 
Materials and Methods

Materials
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy) hexyl ester (CV-159) was synthesized according to the method described elsewhere (2) . Briefly, reaction of 6-chlorohexanol with 3-phenyl-5-pyrazolone in the presence of K 2 CO 3 in dimethylformamide yields 6-(5-phenyl-3-pyrazolyloxy) hexyl alcohol. Esterification of the compound with diketene in the presence of triethylamine yields the crystalline acetoacetate derivative. Reaction of the compound with ammonium carbonate in refluxing methanol yields 3-amino-crotonic acid 6-(5-phenyl-3-pyrazolyloxy) hexyl ester. Finally, the compound is cyclized with methyl 3-nitorobenzylidene acetoacetate in ethanol. The chemical structure of CV-159 is presented elsewhere (1 -3). Nicardipine hydrochloride was synthesized according to the previously described method (9) .
Reagent sources were as follows: TNF-α (Roche Applied Science, Mannheim, Germany); 30% Η 2 Ο 2 (Kanto Kagaku, Tokyo); SP600125 (Jena Bioscience, Jena, Germany); SB203580 (Calbiochem, San Diego, CA, USA); EUK134 (Cayman, Ann Arbor, MI, USA); Nacetyl-L -cysteine (NAC) and W-7 (Sigma Aldrich, St. Louis, MO, USA); N G -nitro-L -arginine methyl ester ( L -NAME) (Dojindo, Kumamoto).
Antibody sources were as follows: phospho-JNK and phospho-p38 (Promega, Madison, WI, USA); phospho-NF-κ B p65 (Ser536) and total JNK2 (Cell Signaling, Beverly, MA, USA); I κ B-α , vascular cell adhesion molecule-1 (VCAM-1), total p38, and total NF-κ B p65 (Santa Cruz Biotech, Santa Cruz, CA, USA); e-selectin and intercellular adhesion molecule-1 (ICAM-1) (R&D System, Minneapolis, MN, USA); total actin (Sigma Aldrich).
Cell culture
Human umbilical vein endothelial cells (HUVECs) were obtained from Kurabo (Osaka) and cultured in Medium 200 supplemented with low serum growth supplement (Cascade Biologics, Portland, OR, USA) as described previously (10, 11) . Cells at passages from 4 to 7 were used.
Western blotting
Western blotting was done as described previously (10 -12) . Protein lysates were collected by homogenizing HUVECs with lysis buffer containing 1% Triton X-100, 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM β -glycerol phosphate, 1 mM NA 3 VO 4 , 1 μ g/ml leupeptin, and 0.1% protease inhibitor cocktail (Nacalai Tesque, Kyoto). The protein concentration was measured by the bicinchoninic acid method (Pierce, Rockford, IL, USA). Proteins (10 -15 μ g) were separated by SDS-PAGE (7.5%) and transferred to a nitrocellulose membrane (Pall, Ann Arbor, MI, USA). After being blocked with 3% bovine serum albumin (for detecting protein phosphorylation) or 0.5% skim milk (others), membranes were incubated with first antibodies at 4°C overnight and then visualized using horseradish peroxidase-conjugated secondary antibodies (1:10,000 dilution, 1 h) and the ECL-plus system (Amersham Biosciences, Buckinghamshire, UK). Equal protein loading was confirmed by measuring total actin, JNK2, p38, and NF-κ B p65 expression. The results were analyzed by using CS Analyzer 3.0 software (ATTO, Tokyo).
Immunofluorescence staining
Immunofluorescence staining was done as described previously (10, 11) . Cells fixed with 4% paraformaldehyde (pH 7.4) for 10 min at 4°C were permeabilized with 0.1% Triton X-100 for 15 min at room temperature. After being blocked with 5% normal goat serum for 1 h, cells were incubated with NF-κ B (p65) antibody (1:500 dilution) at 4°C overnight followed by fluorescent-conjugated secondary antibody (Alexa Fluor 488, 1:500 dilution, 1 h; Molecular Probes, Eugene, OR, USA). Fluorescence images were obtained using fluorescence microscope (BX-51; Olympus, Tokyo) equipped with a cooled CCD camera (MicroPublisher 5.0 RTV; Roper Japan, Tokyo).
Measurement of intracellular ROS
The effects of CV-159 on TNF-mediated ROS generation in HUVECs were examined by a fluorescence staining using 2′,7′-dichlorodihydrofluorescein diacetate (H 2 DCFDA; Invitrogen, Carlsbad, CA, USA). After treatment for 24 h with TNF-α (10 ng/ml) in the absence or presence of CV-159 (10 μ M), HUVECs were loaded with H 2 DCFDA (10 μ M) for 30 min. H 2 O 2 (300 μ M, 20 min) was used as a positive control. Cell fluorescence images were obtained using fluorescence microscope equipped with cooled CCD camera as described above. Image J (13) software was used for the quantitative analysis of H 2 DCFDA staining.
Statistical analyses
Data are shown as means ± S.E.M. Statistical evaluations were performed by one-way ANOVA followed by Tukey's test or the Bonferroni test. Values of P < 0.05 were considered statistically significant.
Results
Effect of CV-159 on TNF-induced expression of inflammatory adhesion molecule
We first examined whether CV-159 affects TNF induction of various ECs adhesion molecules (e-selectin, VCAM-1, ICAM-1), which promote leukocyte attachment to ECs. TNF-α (10 ng/ml, 24 h)-induced expression of e-selectin was significantly inhibited by CV-159 (10 μ M, 30 min) [TNF: 5.1 ± 0.5-fold relative to the control, n = 8 vs. TNF + CV (10 μ M); 1.9 ± 0.4-fold relative to the control, P < 0.05, n = 4, Fig. 1 ]. In contrast, TNF (10 ng/ml, 24 h)-induced expression of VCAM-1 ( Fig. 2A , n = 3 -8) or ICAM-1 (Fig. 2B , n = 3 -6) was not inhibited by CV-159 (0.1 -10 μ M, 30 min).
Effect of CV-159 on TNF-induced activation of JNK and p38
To explore mechanisms responsible for the inhibitory effects of CV-159 on TNF-induced e-selectin expression, activation of JNK and p38 was examined by Western blotting using phosphorylation-specific antibodies. CV-159 (10 μ M for 30 min) significantly inhibited TNF (10 ng/ml, 20 min)-induced phosphorylation of JNK [TNF: 5.2 ± 0.4-fold relative to the control, n = 9 vs. TNF + CV (10 μ M); 3.5 ± 0.7-fold relative to the control, n = 5, P < 0.05, Fig. 3A ] and p38 [TNF: 3.7 ± 1.2-fold relative to the control, n = 13 vs. TNF + CV (10 μ M); 2.6 ± 1.3-fold relative to the control, n = 9, P < 0.05, Fig. 3B ]. 
Effect of inhibitor of JNK or p38 on TNF-induced expression of e-selectin
To determine whether the inhibitory effect of CV-159 on TNF-induced e-selectin expression is mediated by JNK and p38, we examined effect of an inhibitor of JNK or p38 on TNF-induced e-selectin. Treatment of HUVECs with the specific JNK inhibitor SP600125 (10 μ M, 30 min) or the p38 MAPK inhibitor SB203580 (10 μ M, 30 min) before TNF stimulation (10 ng/ml, 24 h) . After HUVECs were treated with 10 ng/ml TNF for 20 min in the absence or presence of CV-159 (10 μ M, pretreatment for 30 min), total cell lysates were harvested. Activation of NF-κ B was determined by measuring phosphorylation of NF-κ B p65 at Ser536 (n = 9 -13) as well as degradation of I κ B-α protein (n = 3 -6). Equal protein loading was confirmed using total NF-κ B or actin antibody. Phosphorylation of NF-κ B (A) is shown as fold increase relative to the control. ** P < 0.01 vs. Cont, # significantly inhibited TNF-induced e-selectin expression (TNF: 4.0 ± 0.4-fold relative to the control, n = 8 vs. TNF + SP600125; 2.4 ± 0.1-fold relative to the control, P < 0.01, n = 5, Fig. 6A and TNF: 2.4 ± 0.2-fold relative to the control, n = 5 vs. TNF + SB203580; 1.2 ± 0.2-fold relative to the control, P < 0.01, n = 3, Fig. 6B ), suggesting that the JNK and p38 pathways are involved in TNFinduced e-selectin expression.
Effect of antioxidant drugs on TNF-induced expression of e-selectin
To examine whether TNF-induced e-selectin expression is associated with ROS, HUVECs were pretreated with EUK134 (10 μ M, 30 min) or NAC (10 mM, 30 min) before TNF stimulation (10 ng/ml, 24 h). EUK134 is a synthetic superoxide dismutase/catalase memitic (14) . NAC but not EUK134 (n = 6, Fig. 7A ) significantly inhibited TNF-induced e-selectin expression (TNF; 3.6 ± 1.0-fold relative to the control, n = 6 vs. TNF + NAC; 0.8 ± 0.1-fold relative to the control, P < 0.05, n = 6, Fig. 7B ).
Effect of antioxidant drug on TNF-induced activation of JNK, p38, and NF-κB
To examine whether TNF-induced phosphorylation of JNK, p38, and NF-κ B is associated with increased ROS, HUVECs were pretreated with NAC (10 mM, 30 min) before TNF stimulation (10 ng/ml, 20 min). NAC significantly inhibited TNF-induced phosphorylation of JNK (TNF: 4.9 ± 0.7-fold relative to the control, n = 4 vs. TNF + NAC; 2.2 ± 0.4-fold relative to the control, P < 0.01, n = 4, Fig. 8A ) and p38 (TNF: 2.8 ± 0.6-fold relative to the control, n = 4 vs. TNF + NAC; 1.7 ± 0.5-fold relative to the control, P < 0.05, n = 4, Fig. 8B ) but not NF-κ B (n = 4, Fig. 8C ).
Effect of CV-159 on TNF-induced ROS generation
We next analyzed whether CV-159 could prevent TNF-induced ROS generation. TNF (10 ng/ml, 24 h) clearly increased a fluorescent intensity in response to H 2 DCFDA compared with the control (Fig. 9A) . CV-159 After HUVECs were treated with 10 ng/ ml TNF for 24 h in the absence or presence of a JNK inhibitor, SP600125 (A: n = 5) or the p38 inhibitor SB203580 (B: n = 3) (each 10 μ M, pretreatment for 30 min), total cell lysates were harvested. Expression of e-selectin was determined by Western blotting. Equal protein loading was confirmed using actin antibody. Expression of e-selectin is shown as fold increase relative to the control. ** P < 0.01 vs. Cont, ## (10 μ M, pretreatment for 30 min) significantly inhibited TNF-induced ROS generation (TNF: 1.9 ± 0.1-fold relative to the control, n = 3 vs. TNF + CV; 0.9 ± 0.1-fold relative to the control, P < 0.01, n = 4, Fig. 9B ). After HUVECs were treated with 10 ng/ ml TNF for 24 h in the absence or presence of EUK134 (A: 10 μ M, 30 min, n = 6) or NAC (B: 10 mM, 30 min, n = 6), total cell lysates were harvested. Expression of e-selectin was determined by Western blotting. Equal protein loading was confirmed using actin antibody. Expression of e-selectin is shown as fold increase relative to the control. * P < 0.05, ** P < 0.01 vs. Cont, # inhibitory effects of CV-159 on TNF-induced e-selectin expression is attributable to an anti-CaM action, HUVECs were pretreated with nicardipine (0.1 -10 μ M, 30 min) or W-7 (10 μ M, 30 min) before TNF stimulation (10 ng/ml, 24 h). Another dihydropyridine Ca 2+ antagonist, nicardipine, but not a CaM inhibitor, W-7 (n = 4, Fig. 10B ), inhibited TNF-induced expression of e-selectin (TNF: 3.0 ± 0.4-fold relative to the control, n = 10 vs. TNF + nicardipine (10 μ M); 1.6 ± 0.8-fold relative to the control, n = 5, Fig. 10A ), suggesting that the prevention of TNF-induced e-selectin is independent of CaM inhibition, but common among dihydropyridine Ca 2+ antagonists. However, the inhibitory effect on TNF-induced eselectin is higher in CV-159 treatment (62.8% inhibition at 10 μ M) than nicardipine treatment (47.2% inhibition at 10 μ M).
Effect of another dihydropyridine calcium channel antagonist or a CaM inhibitor on TNF-induced expression of e-selectin
Effect of nitric oxide (NO) synthase inhibitor on TNFinduced expression of e-selectin
To finally examine whether inhibition of CV-159 on TNF-induced e-selectin expression is associated with endothelium-produced NO, HUVECs were pretreated with CV-159 (10 μ M, 30 min) in the presence of L -NAME (300 μ M, pretreatment for 20 min) before TNF stimula- -channel antagonist or CaM inhibitor on TNF-induced expression of eselectin. After HUVECs were treated with 10 ng/ml TNF for 24 h in the absence or presence of nicardipine (A: 0.1 -10 μ M, 30 min, n = 5) or W-7 (B: 10 μ M, 30 min, n = 4), total cell lysates were harvested. Expression of e-selectin was determined by Western blotting. Equal protein loading was confirmed using actin antibody. Expression of e-selectin is shown as fold increase relative to the control. * P < 0.05, ** P < 0.01 vs. Cont. tion (10 ng/ml, 24 h). The NO synthase inhibitor L -NAME did not reverse the inhibitory effect of CV-159 on TNFinduced e-selectin (n = 6, Fig. 11 ).
Cont
Discussion
In the present study, we examined effects of treatment of cultured ECs with CV-159 on inflammatory signals and protein expression. CV-159 is a dihydropyridine Ca 2+ -channel antagonist with an anti-CaM property. The major finding of the present study is that CV-159 inhibited TNF-induced expression of e-selectin but not VCAM-1 or ICAM-1 in HUVECs (Fig. 12) . We also found that the inhibition of TNF-induced expression of e-selectin is mediated via suppressing the cellular signal of JNK, p38, and NF-κ B (p65). In addition, it is suggested that CV-159 prevents activation of JNK and p38 through inhibition of ROS, while it prevents activation of NF-κ B (p65) via a ROS-independent manner. It is also demonstrated that the inhibitory effects of CV-159 are independent of CaM antagonism or NO production.
NF-κ B (p65) is known to be responsible for TNF-induced e-selectin expression in HUVECs (15, 16) . TNF was shown to increase NF-κ B (p65) binding to e-selectin promoter in nuclei (17) . In addition, a recent study suggested that NF-κ B (p65) is phosphorylated at serine 536 by I κ -B kinase (IKK) and TNF reporter associated factor family member associated binding kinase 1 (TBK1) (18) . It was demonstrated that this NF-κ B (p65) phosphorylation at serine 536 might be associated with e-selectin transcription. Since CV-159 inhibited phosphorylation of NF-κ B (p65) at serine 536 but inhibited neither degradation of I κ -B α protein nor nuclear translocation of NF-κ B (Figs. 4 and 5) , CV-159 may inhibit e-selectin transcription through inhibiting NF-κ B-DNA binding affinities by preventing IKK and/or TBK1 activation. Further studies are necessary to clarify the mechanism through which CV-159 inhibits the NF-κ B-dependent e-selectin induction.
In the present study, we demonstrated that a general antioxidant drug, NAC, but not a superoxide/catalase mimetic, EUK134 (14) , inhibited TNF-induced expression of e-selectin (Fig. 7) and that CV-159 suppressed TNF-induced ROS generation (Fig. 9 ). These findings suggest that CV-159 inhibits TNF-induced expression of e-selectin presumably via suppressing TNF-induced hydroxy radical (OH − ) production. On the other hand, we found that NAC inhibited TNF-induced phosphorylation of JNK and p38 but not NF-κ B (p65) (Fig. 8) . These data suggest that CV-159 inhibits TNF-induced activation of JNK and p38 in a ROS-dependent manner, whereas it inhibited activation of NF-κ B (p65) in a ROS-independent manner. It remains controversial how CV-159 prevents TNF-induced ROS generation. It was previously reported that azelnidipine, a dihydropyridine Ca 2+ -channel antagonist, inhibited expression of NADH/NADPH oxidase and superoxide production in polyethylene cuff-induced vascular injury of mouse femoral artery (19) . Therefore, Summary of the present results. CV-159 prevents TNF induction of e-selectin in cultured ECs via inhibiting JNK, p38, and NF-κ B phosphorylation. CV-159 prevents JNK and p38 phosphorylation via suppressing ROS production, whereas it prevents NF-κ B phosphorylation via a ROS-independent mechanism. Fig. 11 . Effect of NO synthase inhibitor on TNF-induced expression of e-selectin. After HUVECs were treated with 10 ng/ml TNF and 10 μ M CV-159 for 24 h in the absence or presence of L -NAME (300 μ M, pretreatment for 20 min), total cell lysates were harvested. Expression of e-selectin (n = 3 -6) was determined by Western blotting. Equal protein loading was confirmed using actin antibody. Expression of e-selectin is shown as fold increase relative to the control. ** P < 0.01 vs. Cont and ## P < 0.01 vs. TNF. -channel antagonists are widely used in the treatment of hypertension and have been found to reduce the progression of atherosclerosis in animal models (20 -22) . The atheroprotective effects are thought to be mediated via not only Ca 2+ antagonism but also their pleiotropic effects. In recent studies, the pleiotropic effects have been extensively examined, especially focusing on cardiovascular inflammatory molecules and signals. For example, benidipine and amlodipine but not nifedipine or nitrendipine (3 -10 μ M) inhibited TNFinduced VCAM-1 expression in human aortic ECs (23) . In the same report, it was shown that only benidipine (1 -10 μ M) inhibited TNF-induced ICAM-1 expression. It was also reported that lacidipine, lercanidipine, and amlodipine, but not nimodipine or nifedipine inhibited TNF-induced VCAM-1, ICAM-1, and e-selectin expression in HUVECs (24) . In the present study, we confirmed that CV-159 (10 μ M) significantly inhibited TNF-induced expression of e-selectin but not VCAM-1 or ICAM-1 expression in HUVECs. It was previously reported that nicardipine, amlodipine, and azelnidipine (10 μ M) failed to inhibit TNF-induced phosphorylation of p38 in human neutrophils (25) . Furthermore, neither azelnidipine nor nifedipine inhibited H 2 O 2 -induced activation of p38 in rat neonatal cardiomyocytes (26) . In contrast, azelnidipine but not nifedipine inhibited H 2 O 2 -induced JNK activation in rat neonatal cardiomyocytes. In the present study, we confirmed that CV-159 significantly inhibited TNF-induced phosphorylation of JNK and p38. It was also reported that amlodipine but not verapamil or diltiazem showed antioxidant activity in membrane vesicles reconstituted from phospholipids (27) . It was shown in human neutrophils that TNF-induced superoxide generation was significantly suppressed by amlodipine, nicardipine, cilnidipine, benidipine, efonidipine, nifedipine, and azelnidipine (5 -10 μ M), whereas it was not affected by verapamil or diltiazem (25) . Furthermore, amlodipine and benidipine, but not nifedipine or diltiazem, induced NO synthesis in dog coronary microvessel ECs (28, 29) . In the present study, we confirmed that CV-159 has an antioxidant property but not a NO-producing one. These pleiotropic effects of dihydropyridine Ca 2+ -channel antagonists might contribute to the prevention of atherosclerosis.
In summary, we for the first time demonstrated that CV-159 inhibits TNF-induced expression of e-selectin via suppressing the activation of JNK, p38, and NF-κ B in human vascular ECs. We also showed that CV-159 prevents activation of JNK and p38 through inhibition of ROS, while it prevents activation of NF-κ B (p65) in a ROS-independent manner. Further studies in blood vessels and whole animals might contribute to the development of new clinical applications for the prevention of ischemic cardiovascular disease by using CV-159.
